Braeburn Inc. drugs

1 result
  • brixadi

    (BUPRENORPHINE)
    Braeburn Inc.
    BRIXADI is indicated for treating moderate to severe opioid use disorder in patients who have started with a single dose of transmucosal buprenorphine or are already on buprenorphine. It should be used alongside a comprehensive treatment plan, including counseling and psychosocial support.